Search research articles
Contact Us
Filters
Showing results (241-250 of 311) with videos related to
Page
of 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2006
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Jean Bourhis, Fernando Rivera, Ricard Mesia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
Dirk Strumberg, Heike Richly, Ralf A Hilger, et al.
Frontiers in Molecular Biosciences
|
October 8, 2021
Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment
Anaïs Boisson, Grégory Noël, Manuel Saiselet, et al.
ESMO Open
|
May 13, 2020
ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy
Jose Luis Perez-Gracia, Ahmad Awada, Emiliano Calvo, et al.
Breast Cancer Research and Treatment
|
June 8, 2019
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
Véronique Diéras, Hervé Bonnefoi, Emilio Alba, et al.
Journal of Clinical Medicine
|
May 27, 2026
Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation Patients at Very High Risk of Stroke: A Budget Impact Analysis in Italy
Michele Magnocavallo, Ahmad Awada, Guccio Vagnarelli, et al.
Cancers
|
February 27, 2020
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance
Mohamad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Cancers
|
October 17, 2020
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. <i>Cancers</i> 2020, <i>12</i>, 512
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer
Harold J Burstein, Yan Sun, Luc Y Dirix, et al.
Cancers
|
July 27, 2024
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> 2020, <i>12</i>, 512
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Page
of 32
Search research articles
Search
Showing results (241-250 of 311) with videos related to
Sort By:
Page
of 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2006
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Jean Bourhis, Fernando Rivera, Ricard Mesia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
Dirk Strumberg, Heike Richly, Ralf A Hilger, et al.
Frontiers in Molecular Biosciences
|
October 8, 2021
Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment
Anaïs Boisson, Grégory Noël, Manuel Saiselet, et al.
ESMO Open
|
May 13, 2020
ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy
Jose Luis Perez-Gracia, Ahmad Awada, Emiliano Calvo, et al.
Breast Cancer Research and Treatment
|
June 8, 2019
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
Véronique Diéras, Hervé Bonnefoi, Emilio Alba, et al.
Journal of Clinical Medicine
|
May 27, 2026
Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation Patients at Very High Risk of Stroke: A Budget Impact Analysis in Italy
Michele Magnocavallo, Ahmad Awada, Guccio Vagnarelli, et al.
Cancers
|
February 27, 2020
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance
Mohamad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Cancers
|
October 17, 2020
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. <i>Cancers</i> 2020, <i>12</i>, 512
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer
Harold J Burstein, Yan Sun, Luc Y Dirix, et al.
Cancers
|
July 27, 2024
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> 2020, <i>12</i>, 512
Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Page
of 32